Literature DB >> 31403842

Cholesterol Insights and Controversies From the UK Biobank Study.

Samia Mora1, Seth S Martin1, Salim S Virani2.   

Abstract

Entities:  

Keywords:  Editorials; apolipoproteins B; cholesterol, LDL; lipids; risk

Mesh：

Substances：

Year:  2019        PMID： 31403842      PMCID： PMC6783127          DOI： 10.1161/CIRCULATIONAHA.119.042134

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.

Authors:  Samia Mora; C Lan Chang; M Vinayaga Moorthy; Peter S Sever
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

2.  When should a new test become the current reference standard?

Authors:  Paul Glasziou; Les Irwig; Jonathan J Deeks
Journal:  Ann Intern Med       Date:  2008-12-02       Impact factor: 25.391

3.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

4.  Major lipids, apolipoproteins, and risk of vascular disease.

Authors:  Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

5.  Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Authors:  Michel R Langlois; M John Chapman; Christa Cobbaert; Samia Mora; Alan T Remaley; Emilio Ros; Gerald F Watts; Jan Borén; Hannsjörg Baum; Eric Bruckert; Alberico Catapano; Olivier S Descamps; Arnold von Eckardstein; Pia R Kamstrup; Genovefa Kolovou; Florian Kronenberg; Anne Langsted; Kari Pulkki; Nader Rifai; Grazyna Sypniewska; Olov Wiklund; Børge G Nordestgaard
Journal:  Clin Chem       Date:  2018-05-14       Impact factor: 8.327

6.  Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.

Authors:  Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

7.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Authors:  Erik Ingelsson; Ernst J Schaefer; John H Contois; Judith R McNamara; Lisa Sullivan; Michelle J Keyes; Michael J Pencina; Christopher Schoonmaker; Peter W F Wilson; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

8.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population.

Authors:  Anna Fry; Thomas J Littlejohns; Cathie Sudlow; Nicola Doherty; Ligia Adamska; Tim Sprosen; Rory Collins; Naomi E Allen
Journal:  Am J Epidemiol       Date:  2017-11-01       Impact factor: 4.897

9.  Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.

Authors:  Claire Welsh; Carlos A Celis-Morales; Rosemary Brown; Daniel F Mackay; James Lewsey; Patrick B Mark; Stuart R Gray; Lyn D Ferguson; Jana J Anderson; Donald M Lyall; John G Cleland; Pardeep S Jhund; Jason M R Gill; Jill P Pell; Naveed Sattar; Paul Welsh
Journal:  Circulation       Date:  2019-06-20       Impact factor: 29.690
  9 in total
  5 in total

1.  Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study.

Authors:  Tianci Yao; Weilin Lu; Jinshan Ke; Hao Zhang; Xiaofang Zhao; Bei Song; Ting Liu; Qinmei Ke; Chengyun Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-20       Impact factor: 6.055

2.  Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study.

Authors:  Göran Walldius; Ulf de Faire; Lars Alfredsson; Karin Leander; Peter Westerholm; Håkan Malmström; Torbjörn Ivert; Niklas Hammar
Journal:  PLoS Med       Date:  2021-12-01       Impact factor: 11.069

Review 3.  High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation.

Authors:  Katharina Lechner; Amy L McKenzie; Nicolle Kränkel; Clemens Von Schacky; Nicolai Worm; Uwe Nixdorff; Benjamin Lechner; Johannes Scherr; Oliver Weingärtner; Ronald M Krauss
Journal:  Metab Syndr Relat Disord       Date:  2020-03-02       Impact factor: 1.894

4.  Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke.

Authors:  Shuai Yuan; Bowen Tang; Jie Zheng; Susanna C Larsson
Journal:  Ann Neurol       Date:  2020-10-10       Impact factor: 10.422

5.  Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.

Authors:  Tom G Richardson; Eleanor Sanderson; Tom M Palmer; Mika Ala-Korpela; Brian A Ference; George Davey Smith; Michael V Holmes
Journal:  PLoS Med       Date:  2020-03-23       Impact factor: 11.069
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.